biotechNew
Generate Biomedicines
Generative biology platform designing novel protein therapeutics
weight 0.0Flux 62▴PaidLaunched 2026-06
💸 No earnings reported yet
What it is
Boston biotech using its Chroma generative model to design entirely new protein drugs across antibodies, enzymes and vaccines. Held a ~$425M IPO in early 2026.
How AI plugs in
Generative AI trained on 160k+ structures and 190M+ sequences proposes and optimizes de novo protein therapeutics.
Alternatives & related tools
BiotechImage / Video Models
Chai Discovery
New
Frontier biomolecular structure-prediction models
Science
BiotechImage / Video Models
EvolutionaryScale
New
ESM3 frontier protein language model
Science
BiotechImage / Video Models
Xaira Therapeutics
New
AI-first drug discovery built on generative biology
Science
BiotechResearch
Cradle
New
Generative AI protein engineering for the lab
Science
BiotechImage / Video Models
Profluent
New
AI protein and gene-editor design with atomistic control
Science
BiotechData & Analytics
Insilico Medicine
New
End-to-end AI drug discovery from target to clinic.
Science
★ Reviews
No reviews yet — be the first.Your rating